跳至主要内容
临床试验/ISRCTN24439243
ISRCTN24439243已完成不适用

The evaluation of health benefits of hake consumption in a high cardiovascular risk population: a randomised cross-over open nutritional interventional study

Pescanova S.A. (Spain)0 个研究点目标入组 250 人开始时间: 2010年4月30日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
250

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Aged between 18 and 75 years, either sex
  • 2. Recruited in outpatients clinics of the participant centres
  • 3. Voluntarily agree with the study protocol and give written informed consent
  • 4. Thorough clinical history and informative meeting has been performed
  • 5. Metabolic syndrome (primary intervention). The presence of metabolic syndrome according to 2004 ATP-III (Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults) criteria will be evaluated. According to the latter, for the diagnosis of the metabolic syndrome, three or more of the following criteria have to be present:
  • 5.1. Central obesity: waist circumference greater than 102 cm in men and greater than 88 cm in women
  • 5.2. Hypertriglyceridemia: triglycerides greater than or equal to 150 mg/dL (greater than or equal to 1.7 mmol/L) or on treatment
  • 5.3. High density lipoprotein (HDL) less than 40 mg/dL (less than 1.1 mmol/L) in men or less than 50 mg/dL (1.3 mmol/L) in women
  • 5.4. Hypertension: systolic blood pressure greater than or equal to 130 mmHg and/or diastolic greater than or equal to 85 mmHg, or on treatment
  • 5.5. Fasting blood glucose greater than or equal to 100 mg/dL (greater than or equal to 5.6 mmol/L) or any other carbohydrate metabolism disorder (including diabetes and glucose intolerance)

排除标准

  • Those who presented any of the following after a thorough clinical history:
  • 1. Previous allergy to fish or Anisakis infection
  • 2. Morbid obesity (body mass index [BMI] greater than 40)
  • 3. Chronic renal failure
  • 4. Creatinine clearance (CrCl) greater than 30
  • 5. Chronic psychopathology
  • 6. Malignancy
  • 7. Refuse to participate
  • 8. Fibrates treatment

研究者

发起方
Pescanova S.A. (Spain)

相似试验